Edward Michael Kaye

Summit, Sarepta in $584M-plus DMD pipeline licence pact in Europe

view source

• Edward Kaye, Sareptas CEO, said: This partnership with Summit Therapeutics furthers our commitment to invest in innovative approaches to treating Duchenne and supports our common goal of improving the lives of patients with DMD.
• Date: Oct 04, 2016
• Category: Business
• Source: Google

Reborn with its Duchenne drug, Sarepta sees its stock soar 14%

view source

• Throughout the process, interim chief executive Edward Kaye said employees were heartened by the example of the 12 boys suffering from the muscle-wasting disease who took part in Sareptas clinical trial.
• Date: Sep 20, 2016
• Category: Health
• Source: Google

FDA committee suggests not approving experimental drug for Duchenne

view source

• In a confident opening presentation, Sarepta and specialists working as consultants presented data showing that the drug had an effect on the disease, leading to an average gain in the distance boys could walk of 531 feet -or nearly two football fields, Sarepta interim chief executive Edward Kaye sa
• Date: Apr 27, 2016
• Category: Health
• Source: Google

Sarepta Therapeutics (SRPT) Issues Commentary on Adverse FDA Panel Vote for Eeplirsen in DMD

view source

• We would like to thank the hundreds of patients and families who participated in the discussion today, underscoring the critical unmet need of people living with Duchenne. said Edward Kaye, M.D., Sareptas interim chief executive officer and chief medical officer. We appreciated the opportunity t
• Date: Apr 26, 2016
• Category: Business
• Source: Google

FDA committee votes against approval of controversial muscular dystrophy drug

view source

• presentation, the company and specialists working as consultants presented data showing that the drug had an effect on the disease, leading to an average gain in the distance boys could walk over 6 minutes of 162 meters or nearly two football fields, as Sarepta interim chief executive Edward Kaye s
• Date: Apr 25, 2016
• Source: Google

Sarepta (SRPT) Hasn't Recieved Notice Related to Rescheduled Eteplirsen Panel; Will Consolidate Facilities in Mass.

view source

• For a biotechnology company of our size and stage of development, it is operationally important to centralize our facilities and focus our efforts on the R&D, manufacturing, and pre-commercialization of eteplirsen, said Edward Kaye, Sareptas interim chief executive officer and chief medical o
• Date: Mar 08, 2016
• Category: Business
• Source: Google

Company Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Receives Notification of PDUFA Extension for Eteplirsen

view source

• to bring treatment to patients with Duchenne as quickly as possible, we appreciate the efforts of the FDA to conduct a complete review of all of the data supporting our NDA and we remain committed to working closely with them throughout the remainder of the regulatory process, said Edward Kaye, Sa
• Date: Feb 08, 2016
• Category: Health
• Source: Google

FDA Denied Drisapersen: Boosts Sarepta Therapeutics Inc

view source

• In the meantime, Sarepta and BioMarin have escalated their competitive rivalry with each other. Interim CEO Edward Kaye speaking on behalf of Sarepta narrated that his company aggressively working on deals will result in the emergence of new muscle-boosting treatments. He has strong faith that etepl
• Date: Nov 23, 2015
• Category: Health
• Source: Google

Friends:

Martyn Kaye

Friends:

Brooke Larsen, Dani Belanger, Sally Henne, Rachel Worm

Friends:

Sophie Bonham, Sally Flower, Julian Strutt, James Nicholls, Mark Harper

Graduates:

Tammy Johnson (1975-1981),
Edward Kaye (1969-1973),
Joshua Kaplan (1992-1993),
Cynthia Bezanson (1966-1968)

Graduates:

Edward Kaye (1975-1979),
Edward Rayner (1976-1980)

Work:

Western Union Business Solutions - Communications Specialist (Copywriter/Editor) (2013)
Western Union Business Solutions - Copywriter (2012-2013)
Western Union Business Solutions - Assessment Representative (2010-2011)
Western Union Business Solutions - Enrolment Representative (2010-2010)
Maxxam Analytics - Microbiologist (2008-2009)
AXYS Analytical Services - Instrument Chemist (2005-2008)
Laleham Healthcare - QC Chemist (2002-2004)

Education:

Oxford Brookes University - BSc Biology (Hons), Camson College - Diploma in Applied Chemistry and Biotechnology, The Academy of Contemporary Music - Diploma in Contemporary Music, Alton College - A Levels - Various, Perins School - GCSEs - Various

Relationship:

Single

About:

I'm a professional writer/editor, and a former microbiologist and biochemist. I love music, reading, birds, guitar, cycling, and lots of nerdy things.

Tagline:

Comics, Metal, and Parrots—that's all you really need to know!

Bragging Rights:

I'm a writer, scientist, and musician—watch out Buckaroo Banzai!